Jay Andersen, MD
Hematology & Oncology · Portland, ORNPI 1922001023
Payments from drug & device makers
Across 1,102 payments — averaging $7519.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4.5M
- Eli Lilly$1.4M
- Merck$840K
- Novartis$588K
- Genentech, Inc.$389K
- Sanofi US Services Inc.$176K
- plus $410K from 17 others
Across 15 payments — averaging $1270.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$14K
- Eli Lilly$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $4,471,929 |
| Eli Lilly | 33 | $1,412,437 |
| Merck | 439 | $839,559 |
| Novartis | 5 | $587,551 |
| Genentech, Inc. | 251 | $388,970 |
| Sanofi US Services Inc. | 50 | $176,296 |
| Pfizer | 39 | $153,388 |
| Seagen Inc. | 64 | $94,233 |
| Daiichi Sankyo Inc. | 62 | $60,824 |
| Gilead | 19 | $23,817 |
| Puma Biotechnology, Inc. | 28 | $23,643 |
| Janssen Research & Development, LLC | 9 | $23,421 |
| F. Hoffmann-la Roche AG | 8 | $14,396 |
| Genentech USA, Inc. | 7 | $6,821 |
| G1 Therapeutics, Inc. | 5 | $5,625 |
| Athenex Pharmaceutical Division, LLC | 2 | $2,750 |
| Astrazeneca UK Limited | 2 | $270 |
| GE HealthCare | 1 | $133 |
| Stemline Therapeutics Inc. | 1 | $120 |
| Biontech SE | 1 | $79 |
| Astellas Pharma US Inc | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$8,286,345 in reported general payments places this provider in the 95th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Portland
- Michael HeinrichPortland$25M
- Elie TraerPortland$6.5M
- Jacqueline VukyPortland$5.4M
- Sandeep MashruPortland$4.6M
- Abdul Hai MansoorPortland$3.5M
- Aimee KohnPortland$3.3M
- Tibor KovacsovicsPortland$2.7M
- Emerson ChenPortland$2.5M
- Brian DrukerPortland$2.5M
- Tony HoPortland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.